TUESDAY OCTOBER, 11st WEDNESDAY OCTOBER, 12ND
|
|
|
- Blanche Flynn
- 8 years ago
- Views:
Transcription
1 FROM OCTOBER 11 to 14, 2011 BELLEVUE CENTER OF CONGRESS, BIARRITZ THS 10 SCHEDULE (may be changed) TUESDAY OCTOBER, 11st 5-7 PM : THS10 CONGRESS OPENING SESSION 5PM DEBATE/CONFERENCE 7PM END 9AM PLENARY SESSION : ADDICTIONS Stress and addiction Mary Jeanne KREEK (New York) WEDNESDAY OCTOBER, 12ND Opioid Maintenance : terminable or interminable? Herbert KLEBER (New York) Neuroscience and the DSM 5 Definition of Addiction Charles O BRIEN (Philadelphie), Abuse liability of maintenance medications for opioid dependence Sandra COMER (New York) Titre à déterminer Nora VOLKOW (Bethesda) 13 :00 2 :30 PM LUNCH 2 :30 4:30PM
2 PLENARY SESSION : RECENT DEVELOPMENTS ABOUT COCAÏNE ADDICTION Medications to treat concurrent opiate and cocaine dependence Ivan MONTOYA (Bethesda) Vaccines for Cocaine Abuse: Current Status Franck ORSON (Houston) Naltrexone reduces the abuse liability of amphetamine but not cocaine Sandra COMER (New York) Prize based contingency management for cocaine dependence: a 24-week randomized controlled trial/ preliminary results Sylvie PETITJEAN (Bâle) WORKSHOPS WORKSHOP 1: FROM PROHIBITION TO DRAGON DOMESTICATION : WHAT ABOUT EDUCATION? Président: Pascal COURTY (Clermont Ferrand) Modérateur: Patrick BEAUVERIE (Paris) Risks taking during first IV use in France: primary results of the Priminject survey Anne GUICHARD (Paris) Therapeutic education and OST: are drug users educable? By who? Pascal COURTY (Clermont Ferrand) Education to harm linked to IV use Valère ROGISSARD (Paris), et Marie DEBRUS (Paris) Peer education Elisabeth AVRIL (Paris) Caring for therapeutic observance Marie Line RAYNAL (Ville) WORKSHOP 2 : CANNABIS, CARE AND ALL AROUND Moderation : Michel REYNAUD (Villejuif) and Amine BENYAMINA (Villejuif) Presentation of the INCANT Project Olivier PHAN (Paris) Assessment of addictive and psychiatric disorders Alain DERVAUX (Paris) Neuroscience and cannabis: some reflection trails Amine BENYAMINA (Villejuif)
3 WORKSHOP 3 : FORUM HIV, HCV AND ADDICTIONS Moderation: Eric MERLET (Paris) Network Caring service : For a better care of vulnerable people suffering from HCV François PONSIN (Bruxelles) Jacques SCHUMANN (Charleville-Mézières) Care access and HIV /AIDS and HCV screening Folly ANYOVI (Lomé) Algerian example of care of «hépatants» patients Saadi BERKANE (Alger) What lobbyings and strategies for a better care of heptitis in Africa? Djénéba TOURE (Bamako) A new concern about HCV transmission in IV drug users Elise ROY (Montréal) WORKSHOP 4 : THS FROM NORTH TO SOUTH Moderation : Gilles RAGUIN (Paris) and Patrick BEAUVERIE (Paris) Prevalence of infections in IDU in Dakar Sandra PERROT (Paris) Operational research HIV/IDU in Vietnam Laurence WEISS (Paris) African drug users women Fatima Asouab (Rabat) 4:30 Pause 5 :00 7 :00PM PLENARY SESSION : PSYCHE AND DRUGS Spirituality and addiction Jacques BESSON (Genève) Positive psychology François CRESPO (Genève) Neurobiology and psychoanalysis: to a convergence? Georges-Henri MELENOTTE (Strasbourg)
4 WORKSHOPS WORKSHOP 1 : TOBACCO, CLINICAL ASPECTS TO KNOW (Tobacco French Society) Moderation : Didier TOUZEAU (PARIS) Tobacco Consumption in polydrugs users in addiction treatment Frédéric SORGE (Paris) Suicidal behaviour and suicides in smokers and ex smokers. Role of dual disorders. Ivan BERLIN (Paris) Treatment of tobacco addiction in HIV patients Nathalie WIRTH (Nancy) Results of smoking prohibition in public places Brigitte BENEZECH (Ville) WORKSHOP 2: FAST TESTS Modération : Pascal MELIN (Saint Dizier) Development of communautary health actions in harm reduction centers Anthony BROUARD (Bordeaux) Jean-Yves LE TALEC (Toulouse) ACTIS : two approaches, one partnership Michel COLLS (Saint-Etienne) YOZ - Fast tests to facilitate screening among precarious populations Gérald PONSARD (Charleville Mézières) Marie Dominique PAUTI (Paris) WORKSHOP 3 : PRISON AND CARE Chair : Florence AUBENAS (Paris) Moderation : Gabriel MOUESCA (Bayonne) Sick prisons Saâdia YAKOUB (Paris) From penitentiary medicine to medicine in penal institution : truth and drifts Fadi MEROUEH (Villeneuve les Maguelonne) Long penalties and care access : the case of political prisoners Mertxe COLINA (Bayonne)
5 Medicals in prison : relation with prisoners and with penal institution François BES (Paris) Medicine in Algerian prisons : past, present and future Mohamed-Salah LAIDLI (Alger) 7 PM Fin THURSDAY OCTOBER, 13RD 8 :30 9 :30 AM PLENARY SESSION 1: DRUG CONSUMPTION ROOMS Moderation: Patrizia CARRIERI (Marseille) and Teresa MAURA (Bilbao) The science and politics of Insite: inside the evaluation of Vancouver s supervised injection site Thomas KERR (Vancouver) 9 :45 11 :15 PLENARY SESSION 2 OPIATE SUBSTITUION TREATMENTS Chair: Jean-Jacques DEGLON (Genève) and Mary Jeanne KREEK (New York) OST and professional practices Brigitte REILLER (Bordeaux) Methadone, metabolism and cardiotoxicity: an update about biological, clinical and genetic data Chin EAP (Lausanne) Heroin Programs Experience Miguel CASAS (Barcelona) Addiction and pregnancy Gabriele FISCHER (Vienna) 11:30 13:00 PM PLENARY SESSION 3 HEPATITIS Chair: Robert SCHAEFFER (New York) Genetic markers of Hepatitis C progression and response to therapy Christian TREPO (Lyon) HCV: recovery for everyone?
6 Victor DE LEDINGHEN (Bordeaux) Care delivery to hepatitis C infected drug users in French reference centers Philippe CHOSSEGROS (Lyon) 1:00 14:30 PM SATELLITE SYMPOSIUM SCHERING PLOUGH PLENARY SESSION : PHARMACODEPENDENCIES Chairman : Michel MALLARET (Grenoble) Moderation : Nathalie RICHARD (Paris) and Joëlle MICALLEF (Marseille) 2:30 4:30 PM Contribution of drug supervision for clinicians Michel MALLARET (Grenoble) Measurement of Buprenorphine and morphine sulfates Syringes Nicolas AUTHIER (Clermont Ferrand) WORKSHOPS INSERM expert s report about medicine drugs dependency Xavier THIRION (Marseille) Misuse of Methyl-Phenidate Joelle MICALLEF (Marseille) Passive poisoning with marihuana : the fish tank syndrome Nicolas AUTHIER (Clermont Ferrand) WORKSHOP1 : ALCOHOL : AROUND THE BENEFITS/RISKS POLITICS Co-Chairmen: Michel REYNAUD (Villejuif) and Amine BENYAMINA (Villejuif) Moderation : Clinical trial with Baclofène Phillipe JAURY (Paris) Alcohol : can reduced consumption be a therapeutical goal? Henri-Jean AUBIN (Paris) The «Alcoochoix Program» Experience Eva SEKERA (Genève) WORKSHOP 2 : ORGANIZATION OF HCV AND HBV CARE IN PRIVATE PRACTICE Moderation : Xavier AKNINE (Bondy)
7 Role and place of medical microstructures Georges Henri MELENOTTE (Strasbourg) Addiction centers mobile consulting in GP s offices (Episea) Pascale BOUTHILON (Paris) Proximity mini networks : role and function Sibel BILAL (Paris) et Philippe GRUNBERG (Gagny) HCV Health care organization in a medical and familial clinic Julie LOSLIER (Québec) WORKSHOP 3 : NEUROBIOLOGY WORKSHOP 4: NEW CHALLENGES FOR HARM REDUCTION Puting harm reduction back on public debate Pierre CHAPPARD (Paris) Populations neglected by harm reduction Patrizia CARRIERI (Marseille) Harm reduction and addiction centers: impossible task? Brigitte REILLER (Bordeaux) Pharmasud project and needle exchange by air mail Catherine DUPLESSY (Paris) 4 :30 5 :00 Pause 5:00 SATELLITE SYMPOSIUM RECKITT BENCKISER 7:00 End 8:00 PM CONGRESS DINNER
8 FRIDAY OCTOBER, 14TH 9:00 10:45 AM PLENARY SESSION HIV AND DRUG USE 30 years of AIDS Daniel ZULAIKA (San Sebastian) Mortality and morbidity in 2011 in people suffering from HIV in Northern countries Laurence WEISS (Paris) Prevention and treatment of HIV/AIDS among drug using population: NIDA s research priorities Jacques NORMAND (Bethesda) 11:00 13 :00 AM PLENARY SESSION : HARM REDUCTION Patrizia CARRIERI (Marseille) Indetermined title John STRANG (London) Positive impact of HCV treatment initiation on adherence to HIV treatment in co-infected patients: implications for access to HCV care Perrine ROUX (Marseille) Legal Obstructions to HIV Prevention among Drug Injectors in Ukraine Robert BOOTH (Denver) Transitions from concentrated HIV epidemics among people who injected drugs to self-sustained heterosexual HIV epidemics Don DES JARLAIS (New York) 1:00 2:30 PM 2:30 4:00 PM WORKSHOPS SESSION POSTERS - SESSION POSTERS - SESSION POSTERS - SESSION POSTERS WORKSHOP 1 : ATTACHMENT DISORDER AND DRUG USE Moderation : Philippe CHOSSEGROS (Lyon) Clinical aspects of attachment disorders in dependent subjects Sabine MOUCHET MAGES (Lyon) Bringing of neurosciences to understanding attachment disorders in drug addicts Lucie PENNEL (Grenoble)
9 Attachment disorders and eating disorders in adolescents Frédéric ATGER (Paris) Family care of drug users in jail Bertrand LEGEAY (Nantes) WORKSHOP 2: NEW TREATMENTS OF HCV AND HBV Moderation : Pascal MELIN (Saint Dizier) Care delivery to HCV drug users under OST : a multiple challenge Pascal COURTY (Clermont Ferrand) Screening, evaluation and hepatitis care in psychosocial rehab Jean-Philippe LANG (Erstein) Juliette FOUCHER (Bordeaux) Malek ABAZID (Paris) WORKSHOP 3 : ADDICTION AND DUAL DISORDERS 4:30 5:00 Pause 5:00 6:00 PM CLOSING SESSION
11th International Congress
11th International Congress From October 8 to 11, 2013»»» Bellevue Center of Congress Biarritz - France www.ths-biarritz.com /// Plenary sessions /// Debates /// Workshops /// Posters Addiction Hepatitis
How can we better treat drug addiction? New scientific and clinical challenges for Europe
December 9th and 10th, 2008 The Grand Amphitheater of the Sorbonne European Conference of Scientific Experts How can we better treat drug addiction? New scientific and clinical challenges for Europe Languages
Biarritz Meeting. 12th International Congress
Biarritz Meeting 12th International Congress Addictions - Hepatitis - AIDS - (ATHS) Program September 29 - October 2nd, 2015 Bellevue Center of Congress - Biarritz plenary sessions, debates, workshops,
24 Elisad annual meeting Arezzo 11-13 October 2012
24 Elisad annual meeting Arezzo 11-13 October 2012 From addiction to consumption: The evolution of the phenomenon and the interventions of services The big change:back to the late 90 and the zero decade
MORTALITY AMONGST ILLICIT DRUG USERS
MORTALITY AMONGST ILLICIT DRUG USERS Over the past 40 years the rate of illicit drug use worldwide has risen dramatically, and with it the number of deaths reported among drug-using populations. What are
Science addressing drugs and HIV: State of the Art. Vienna
Science addressing drugs and HIV: State of the Art 2 nd Scientific Statement: March 2016 Vienna Context In March 2014, UNODC organized within the frame of the High-level Review of the 57 th session of
Scientific Facts on. Psychoactive Drugs. Tobacco, Alcohol, and Illicit Substances
page 1/5 Scientific Facts on Psychoactive Drugs Tobacco, Alcohol, and Illicit Substances Source document: WHO (2004) Summary & Details: GreenFacts Context - Psychoactive drugs such as tobacco, alcohol,
Non medical use of prescription medicines existing WHO advice
Non medical use of prescription medicines existing WHO advice Nicolas Clark Management of Substance Abuse Team WHO, Geneva Vienna, June 2010 clarkn@who.int Medical and Pharmaceutical role Recommendations
Impact of Systematic Review on Health Services: The US Experience
Impact of Systematic Review on Health Services: The US Experience Walter Ling MD Integrated Substance Abuse Programs (ISAP) UCLA The effectiveness of interventions for addictions: The Drug and Alcohol
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)
SROM (oral morphine) an add on medication for the treatment of opioid dependence: risks & benefits. Gabriele Fischer. Medical University Vienna
ATHS Biarritz oct 1 th, 2015 SROM (oral morphine) an add on medication for the treatment of opioid dependence: risks & benefits Gabriele Fischer gabriele.fischer@meduniwien.ac.at Medical University Vienna
Introduction to Substance Abuse Issues in Canada: Pathways, Health Implications and Interventions
Introduction to Substance Abuse Issues in Canada: Pathways, Health Implications and Interventions Maritt Kirst, PhD Centre for Research on Inner City Health, St. Michael s Hospital OTC Summer Institute
Clinical Priorities for Alcohol and Drugs in Public Health
Clinical Priorities for Alcohol and Drugs in Public Health What do we need to Measure up to? Dr Michael Kelleher Clinical Lead Alcohol and Drugs Team, Health and Wellbeing Directorate SMMGP 8 th Primary
We include a series of recommended questions for the Swedish delegation at the end of our letter.
United Nations Committee on Economic Social and Cultural Rights Palais Wilson CH 1211 Geneva 10 Switzerland 2 October 2008 Re: Review of Sweden s fifth periodic report, 41 st Session of the Committee on
Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011
Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids
Patients are still addicted Buprenorphine is simply a substitute for heroin or
BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module VI: Myths About the Use of Medication in Recovery Patients are still addicted Buprenorphine is simply a substitute
Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
Neurobiology of Addiction. Bench to Bedside: From the Science to the Practice of Addiction Medicine. Outline
Bench to Bedside: From the Science to the Practice of Addiction Medicine Petros Levounis, MD, MA Chair, Department of Psychiatry Rutgers New Jersey Medical School ADDICTION MEDICINE ACADEMY Clearwater
Rekindling House Dual Diagnosis Specialist
Rekindling House Dual Diagnosis Specialist Tel: 01582 456 556 APPLICATION FOR TREATMENT Application Form / Comprehensive Assessment Form Please provide as much detail as you can it will help us process
DMRI Drug Misuse Research Initiative
DMRI Drug Misuse Research Initiative Executive Summary Dexamphetamine Substitution as a Treatment of Amphetamine Dependence: a Two-Centre Randomised Controlled Trial Final Report submitted to the Department
Title: Opening Plenary Session Challenges and Opportunities to Impact the Opioid Dependence Crisis
The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org,
Like cocaine, heroin is a drug that is illegal in some areas of the world. Heroin is highly addictive.
Heroin Introduction Heroin is a powerful drug that affects the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants to.
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the
Development of the guidelines on the pharmacotherapy of addiction case study Croatia
Development of the guidelines on the pharmacotherapy of addiction case study Croatia Croatia Marina Kuzman Dragica Katalinic Croatian National Institute of Public Health Cyprus, 2009. Drug use and drug
DrugFacts: Treatment Approaches for Drug Addiction
DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please
Drug treatment in East and SE Asia: - the need for effective approaches
Drug treatment in East and SE Asia: - the need for effective approaches Professor Nick Crofts Director, Turning Point Alcohol and Drug Centre Director, UNODC Technical Resource Centre for Drug Treatment
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment
Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse
Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine
Opioid Addiction & Corrections
Opioid Addiction & Corrections Medication Assisted Treatment in the Connecticut Department of Correction April 30, 2015--CJPAC Kathleen F. Maurer, MD, MPH, MBA Medical Director and Director of Health and
Jennifer Sharpe Potter, PhD, MPH Associate Professor Division of Alcohol and Drug Addiction Department of Psychiatry
Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings From Starting Treatment With Agonist Replacement Therapies (START) Jennifer
MSc International Programme in Addiction Studies. Prospectus 2015-2016
MSc International Programme in Addiction Studies Prospectus 2015-2016 The Institute of Psychiatry, Psychology and Neuroscience www.kcl.ac.uk/ioppn The Institute of Psychiatry, Psychology and Neuroscience
Heroin Addiction and Drug Policy The British System
Heroin Addiction and Drug Policy The British System C Edited by JOHN STRANG Getty Senior Lecturer in the Addictions and Deputy Director Addiction Research Unit, National Addiction Centre, The Maudsiey/Institute
Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
Alcoholism, Drug Addiction, and the Road to Recovery
Alcoholism, Drug Addiction, and the Road to Recovery Life on the Edge Barry Stimmel, MD The Haworth Medical Press An Imprint of The Haworth Press, Inc. New York London Oxford CONTENTS Preface Acknowledgments
SOMERSET DUAL DIAGNOSIS PROTOCOL OCTOBER 2011
SOMERSET DUAL DIAGNOSIS PROTOCOL OCTOBER 2011 This document is intended to be used with the Somerset Dual Diagnosis Operational Working guide. This document provides principles governing joint working
The Clinical Content of Preconception Care: Alcohol, Tobacco, and Illicit Drug Exposures
The Clinical Content of Preconception Care: Alcohol, Tobacco, and Illicit Drug Exposures by R. Louise Floyd, DSN, RN; Brian W. Jack, MD; Robert Cefalo, MD, PhD; Hani Atrash, MD, MPH; Jeanne Mahoney, BSN,
John R. Kasich, Governor Orman Hall, Director
John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic
Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course
The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org,
REVIEW OF DRUG TREATMENT AND REHABILITATION SERVICES: SUMMARY AND ACTIONS
REVIEW OF DRUG TREATMENT AND REHABILITATION SERVICES: SUMMARY AND ACTIONS 1. INTRODUCTION 1.1 Review Process A Partnership for a Better Scotland committed the Scottish Executive to reviewing and investing
The prevalence of use of psychotropic drugs, buprenorphine and methadone on the streets, the polyuse of substances in Finland
The prevalence of use of psychotropic drugs, buprenorphine and methadone on the streets, the polyuse of substances in Finland Hannu Alho, Professor Unit on Prevention and Treatment of Addictions, National
Treatment of opioid use disorders
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
Testimony of The New York City Department of Health and Mental Hygiene. before the
Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of Opioid
Oral Morphine Treatments (in opioid dependence)
Oral Morphine Treatments (in opioid dependence) Gabriele Fischer gabriele.fischer@meduniwien.ac.at Medical University Vienna Biarritz oct 10th, 2013 Conflict of Interest Reckitt Benckiser/Shering Plough
Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio
Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,
INJECTION DRUG USE AND ITS INTERVENTIONS IN AFRICA: THE FORGOTTEN CONTINENT Some Examples From Tanzania
INJECTION DRUG USE AND ITS INTERVENTIONS IN AFRICA: THE FORGOTTEN CONTINENT Some Examples From Tanzania Jessie Kazeni MBWAMBO, Senior Researcher and Psychiatrist (Muhimbili University Teaching Hospital)
April 23, 2015. are dependent on the nonmedical use of prescription pain medicines and heroin.
STATEMENT OF ROBERT L. DUPONT, MD PRESIDENT, INSTUTUTE FOR BEHAVIOR AND HEALTH, INC BEFORE THE HOUSE SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS REGARDING COMBATTING THE OPIOID ABUSE EPIDEMIC: PROFESSIONAL
Specialist Alcohol & Drug Services in Lanarkshire
Specialist Alcohol & Drug Services in Lanarkshire This brochure describes what help is available within Lanarkshire s specialist treatment services. These include the North Lanarkshire Integrated Addiction
Evaluating OST programmes MMT and drug treatment in the Maldives
Evaluating OST programmes MMT and drug treatment in the Maldives Prof Gerry Stimson Based on A PROCESS AND SYSTEMS EVALUATION OF THE DRUG TREATMENT AND REHABILITATION SERVICES IN THE MALDIVES. Gordon Mortimore
SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK
National Institute on Drug Abuse SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK U.S. Department of Health and Human National Institutes of Health SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK The goal
Pekka Heinälä Multiple substance use a challenge for treatment and prevention
Pekka Heinälä Multiple substance use a challenge for treatment and prevention Finn-Czech Media Seminar on Substances Addicted Society today and in the future Prague 9 through 12 September 2010 Multiple
Positive impact of HCV treatment initiation on health outcomes in injecting drug users
Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction
4/13/2011. 5 Actions to Overcome Addiction. John Fitzgerald, PhD, LPC, CAS. relationships
5 Actions to Overcome Addiction John Fitzgerald, PhD, LPC, CAS relationships 1 What is addiction? 2 Socially-constructed 3 Risk Factors 80% 15 years-old Addiction Protective Factors Risk Factors Domain
Treatments for drug misuse
Understanding NICE guidance Information for people who use NHS services Treatments for drug misuse NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases and
Gender and drug use: Challenges for communication
Gender and drug use: Challenges for communication Pratima Murthy Professor of Psychiatry and Chief, Centre for Addiction Medicine NIMHANS, Bangalore, India Presentation made on behalf of the UNODC, ROSA
SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK
National Institute on Drug Abuse SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK U.S. Department of Health and Human National Institutes of Health SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK The goal
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SPECIAL HEALTH AUTHORITY TENTH WAVE WORK PROGRAMME DRUG MISUSE. Psychosocial interventions in drug misuse
Attachment B NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SPECIAL HEALTH AUTHORITY TENTH WAVE WORK PROGRAMME DRUG MISUSE Psychosocial interventions in drug misuse On 16 th June 2004 the Department of Health
EPIDEMIC 4.6 % OF INDIVIDUALS 18 25 USED PAIN RELIEVERS FOR NON-MEDICAL REASONS. 1.5 MILLION YOUNG ADULTS USED PAIN RELIEVERS IN THE PAST MONTH.
Drug Court EPIDEMIC In the 10 years (1997 2007) the per capita retail purchases of Methadone, Hydrocodone and Oxycodone in the United States increased 13-fold, 4-fold and 9-fold, respectively. 4.6 % OF
Alcohol and drugs prevention, treatment and recovery: why invest?
Alcohol and drugs prevention, treatment and recovery: why invest? 1 Alcohol problems are widespread 9 million adults drink at levels that increase the risk of harm to their health 1.6 million adults show
Depot Naltrexone Appears Safe and Effective for Heroin Addiction
of 2 http://www.drugabuse.gov/nida_notes/nnvol21n3/depot.html 10/20/2011 11:23 AM NIDA NEWS NIDA Home > Publications > NIDA Notes > Vol. 21, No. 3 > Research Findings Depot Naltrexone Appears Safe and
NOUVELLE PRÉOCCUPATION CONCERNANT LA TRANSMISSION DU VIRUS DE L HÉPATITE C CHEZ LES USAGERS DE DROGUES INJECTABLES À MONTRÉAL, CANADA
Le Colloque Européen et International THS Biarritz,11 au 14 octobre 2011 NOUVELLE PRÉOCCUPATION CONCERNANT LA TRANSMISSION DU VIRUS DE L HÉPATITE C CHEZ LES USAGERS DE DROGUES INJECTABLES À MONTRÉAL, CANADA
Medication treatments for opioid use disorders
Medication treatments for opioid use disorders Summary for counties JUDITH MARTIN, Medical Director of Substance Use Services, San Francisco Department of Public Health Brief history of Methadone and Buprenorphine
Federal Response to Opioid Abuse Epidemic
Healthcare Committee Federal Response to Opioid Abuse Epidemic On May 1, 20215 the Energy and Commerce Subcommittee on Oversight and Investigations held a hearing entitled What is the Federal Government
An integrated approach to addressing opiate abuse in Maine. Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009
An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009 Background Defining the problem: Opiates pain relievers (OxyContin,
Substance Abuse During Pregnancy: Moms on Meds. Jennifer Anderson Maddron, M.D LeConte Womens Healthcare Associates
Substance Abuse During Pregnancy: Moms on Meds Jennifer Anderson Maddron, M.D LeConte Womens Healthcare Associates 2010 National Survey on Drug Use and Health An estimated 4.4% of pregnant women reported
Understanding Addiction: The Intersection of Biology and Psychology
Understanding Addiction: The Intersection of Biology and Psychology Robert Heimer, Ph.D. Yale University School of Public Health Center for Interdisciplinary Research on AIDS New Haven, CT, USA November
National Campaign Against Drug Abuse (NACADA) Authority in Kenya. Center for Substance Abuse Treatment
National Campaign Against Drug Abuse (NACADA) Authority in Kenya Center for Substance Abuse Treatment t C t f S b t Ab T t t Center for Substance Abuse Treatment Substance Abuse Mental Health Services
FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma
FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documents
Richard H. Needle, PhD, MPH Lin Zhao, PhD candidate (UCSF School of Nursing) CSIS Africa Program Roundtable June 10, 2010
Richard H. Needle, PhD, MPH Lin Zhao, PhD candidate (UCSF School of Nursing) CSIS Africa Program Roundtable June 10, 2010 Reference Group to the United Nations on HIV and Injecting Drug Use 2010 Mathers:
CURRICULUM VITAE. Areas of Expertise: Clinical Trials and Behavioral Research, Psychiatry, Addictions, and HIV/AIDS
CURRICULUM VITAE Annet Davis-Vogel, R.N., M.S.W., CCRC University of Pennsylvania HIV Prevention Research 3535 Market Street, Philadelphia, PA 19104 advogel@mail.med.upenn.edu Description of Skills: Project
SC 215 FIGHTING DRUG ADDICTION WITH DRUGS. John Bush April 15, 2013
SC 215 FIGHTING DRUG ADDICTION WITH DRUGS John Bush April 15, 2013 ADDICTION A persistent, compulsive dependence on a behavior or substance Behavioral Compulsive shopping --Compulsive eating Compulsive
Current Model of Drug Care. Components of a Full Drug Care Service
Current Model of Drug Care Treatment Detox Rehab Components of a Full Drug Care Service (1) (2) (3) (4) (5) (6) (7) (8) (9) Community Preparation Treatment Detox Rehab Community Community Prison work Halfway
OVERVIEW WHAT IS POLyDRUG USE? Different examples of polydrug use
Petrol, paint and other Polydrug inhalants use 237 11 Polydrug use Overview What is polydrug use? Reasons for polydrug use What are the harms of polydrug use? How to assess a person who uses several drugs
Drug Situation in Vancouver UHRI. Report prepared by the Urban Health Research Initiative of the British Columbia Centre for Excellence in HIV/AIDS
Drug Situation in Vancouver Report prepared by the Urban Health Research Initiative of the British Columbia Centre for Excellence in HIV/AIDS Second edition June 2013 UHRI U R BAN H EALTH R ESEARCH I NITIATIVE
Hepatitis C Treatment of Active IV Drug Users Tania Dunn, RN Isabelle Gendron, RN B.Sc.
Hepatitis C Treatment of Active IV Drug Users Tania Dunn, RN Isabelle Gendron, RN B.Sc. CRD Le Virage Équipe TDO GMF de l UMF Charles LeMoyne St-Lambert, Quebec February 2012 Potential Conflicts of Interest
P U B L I C H E A L T H A D V I S O R Y
The Commonwealth of Massachusetts Executive Office of Health and Human Services Department of Public Health 250 Washington Street, Boston, MA 02108-4619Tel: 617-624-6000 Fax: 617-624-5206 www.mass.gov/dph
Study Finds Withdrawal No Easier With Ultrarapid Opiate Detox
NIDA - Publications - NIDA Notes - Vol. 21, No. 1 - Research Findings of 4 http://www.drugabuse.gov/nida_notes/nnvol21n1/study.html 10/20/2011 12:06 PM NIDA NEWS NIDA Home > Publications > NIDA Notes >
Congressional Testimony. Laurence M. Westreich, M.D. President, American Academy of Addiction Psychiatry
Congressional Testimony Laurence M. Westreich, M.D. President, American Academy of Addiction Psychiatry Combatting the Opioid Abuse Epidemic: Professional and Academic Perspectives, April 23 rd 2015 Subcommittee
Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:
Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society
How To Treat An Addict
Guidance on Medical Treatment of Drug Abusers in Substitution Treatment for Opioid Dependency Pompidou Treatment Platform, Cyprus, May 2009 Helle Petersen Senior Medical Officer National Board of Health
Hepatitis Services in Substance Abuse Treatment Settings
Hepatitis Services in Substance Abuse Treatment Settings Funding provided by the Center for Substance Abuse Treatment The Matrix Institute Dan George Overview Hx of HCV group s implementation at OTP clinic
Hulpverleningsmodellen bij opiaatverslaving. Frieda Matthys 6 juni 2013
Hulpverleningsmodellen bij opiaatverslaving Frieda Matthys 6 juni 2013 Prevalence The average prevalence of problem opioid use among adults (15 64) is estimated at 0.41%, the equivalent of 1.4 million
DRUG PROBLEM IN THE ARAB REGION. Prof. Mehdi PAES
DRUG PROBLEM IN THE ARAB REGION Prof. Mehdi PAES Introduction The Arab region, with about 300 million inhabitants, is composed of 21 countries covering a large geographic area located essentially in North
THE DATA FOR ADULT DRUG TREATMENT LINCOLNSHIRE LINCOLNSHIRE E08B 32
THE DATA FOR ADULT DRUG TREATMENT LINCOLNSHIRE LINCOLNSHIRE E08B 32 THIS SUPPORTING INFORMATION This pack sets out the investment in drug in your area. It also gives key performance information about your
HARM REDUCTION FOR PEOPLE WHO INJECT DRUGS INFORMATION NOTE
HARM REDUCTION FOR PEOPLE WHO INJECT DRUGS INFORMATION NOTE Introduction The Global Fund supports evidence-based interventions that aim to ensure access to HIV prevention, treatment, care and support for
Medication-Assisted Treatment for Opioid Addiction
Medication-Assisted Treatment for Opioid Addiction This document contains a general discussion of medications approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of opioid
A 10-year follow-up study of drug users in treatment. Grethe Lauritzen, SIRUS
A 10-year follow-up study of drug users in treatment Grethe Lauritzen, SIRUS A prospective co-hort study 10-year observation period (1998-2009) 481 clients interviewed in 20 treatment facilities in and
5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279. Welcome
5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279 Welcome Welcome to Starlight Behavioral Health Opiate Dependence program. At Starlight, we believe that addiction is
PERSPECTIVES ON DRUGS The role of psychosocial interventions in drug treatment
UPDATED 4.6.2015 PERSPECTIVES ON DRUGS The role of psychosocial interventions in drug treatment Psychosocial interventions are structured psychological or social interventions used to address substance-related
AN OVERVIEW OF PROGRAMS FOR PEOPLE WHO INJECT DRUGS
AN OVERVIEW OF PROGRAMS FOR PEOPLE WHO INJECT DRUGS Helgar Musyoki MARPs and Vulnerable Groups Program National AIDs/STI Control Programme November 2012 Background Injection of heroin in Kenya reportedly
Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment
Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Introduction March 3, 2008 By: Suzanne Gelber, MSW, Ph.D., Managing Partner, The Avisa Group Defining Characteristics
Drug Abuse Trends in the Seattle/King County Area: 2013
Drug Abuse Trends in the Seattle/King County Area: 2013 Caleb Banta-Green 1, T. Ron Jackson 2, Steve Freng 3, Michael Hanrahan 4, Cynthia Graff 5, John Ohta 6, Mary Taylor 7, Richard Harruff 8, Robyn Smith
HIGH SUCCESS RATE OF BUTTERY REHABILITATION PROGRAMS
HIGH SUCCESS RATE OF BUTTERY REHABILITATION PROGRAMS By treating addiction and helping people live productive, fulfilling lives, The Buttery addresses a major social and economic problem facing our society.
8 th Annual Addiction Day Conference & Networking Fair Scientific Program
8 th Annual Addiction Day Conference & Networking Fair Scientific Program Thank you for your interest in 8 th Annual Addiction Day & XXVI CSAM Scientific Conference. Please find an overview and learning
From the street to the NICU. Richard Christensen, PA, CAS
From the street to the NICU Richard Christensen, PA, CAS Treatment works Truths Disconnect with pregnant women seeking treatment Disconnect between community and science Medication is not a stand-alone
MEWA HIV and Key Population programming
MEWA HIV and Key Population programming Working With People Who Use Drugs Presented by: ABDALLA BADHRUS Program Manager Health And Harm Reduction Services. Muslim Education And Welfare Association Held
Free Additional Resources
Free Additional Resources Substance Abuse and Mental Health Services Administration Treatment Improvement Protocols The Substance Abuse and Mental Health Services Administration (SAMHSA) offers free Treatment
CANCER SUMMER SCHOOL 2014 PROGRAM
CANCER SUMMER SCHOOL 2014 PROGRAM Monday 30 th June 0 Participant Arrival & Coffee Break ED 3 room Presentation of the program Presentation of the participants and of their research interests/experiences
Addiction Pharmacotherapies in Integrated Systems OPIOIDS
Addiction Pharmacotherapies in Integrated Systems OPIOIDS Univ. Prof. Dr.. Gabriele Fischer Department of Psychiatry Addiction clinic Medical University Vienna DELIVERY SYSTEMS FOR SUBSTANCE ABUSE TREATMENT
drug dependence treatment and care
UNODC-WHO Joint Programme on drug dependence treatment and care The vision Effective and humane treatment for all people with drug use disorders. Nothing less than would be expected for any other disease.